Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 151 AL 165

Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation

Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S.

J Alzheimers Dis. 2010;21(2):361-71. doi: 10.3233/JAD-2010-100150.

[Colivelin--drug therapy for patients with Alzheimer's disease]

Matsuoka M.

Nihon Yakurigaku Zasshi. 2010 Jun;135(6):263.

Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities

Rosenblatt A, Gao J, Mackell J, Richardson S.

Am J Alzheimers Dis Other Demen. 2010 Sep;25(6):483-9. doi: 10.1177/1533317510372923. Epub 2010 Jun 17.

REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state

Panza F, Frisardi V, Imbimbo BP, Capurso C, Logroscino G, Sancarlo D, Seripa D, Vendemiale G, Pilotto A, Solfrizzi V.

CNS Neurosci Ther. 2010 Oct;16(5):272-84. doi: 10.1111/j.1755-5949.2010.00164.x. Epub 2010 Jun 16.

Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?

Martorana A, Esposito Z, Koch G.

CNS Neurosci Ther. 2010 Aug;16(4):235-45. doi: 10.1111/j.1755-5949.2010.00175.x. Epub 2010 Apr 16.

Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials

McArthur RA, Gray J, Schreiber R.

Curr Opin Investig Drugs. 2010 Jul;11(7):740-60.

Antioxidant approaches for the treatment of Alzheimer's disease

Lee HP, Zhu X, Casadesus G, Castellani RJ, Nunomura A, Smith MA, Lee HG, Perry G.

Expert Rev Neurother. 2010 Jul;10(7):1201-8. doi: 10.1586/ern.10.74.

[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]

Wouters CJ, Dautzenberg L, Thissen A, Dautzenberg PL.

Tijdschr Gerontol Geriatr. 2010 Jun;41(3):146-50. doi: 10.1007/BF03096196.

Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels

Timmer NM, van Dijk L, van der Zee CE, Kiliaan A, de Waal RM, Verbeek MM.

Neurobiol Dis. 2010 Oct;40(1):340-7. doi: 10.1016/j.nbd.2010.06.008. Epub 2010 Jun 22.

Alzheimer's disease: clinical trials and drug development

Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M.

Lancet Neurol. 2010 Jul;9(7):702-16. doi: 10.1016/S1474-4422(10)70119-8.

Learning from failure

Nat Rev Drug Discov. 2010 Jul;9(7):499. doi: 10.1038/nrd3222.

Animal models of Alzheimer's disease: an understanding of pathology and therapeutic avenues

Obulesu M, Rao DM.

Int J Neurosci. 2010 Aug;120(8):531-7. doi: 10.3109/00207451003760080.

[Effect of compound Polygonum multiflorum extract on Alzheimer's disease]

Chen L, Huang J, Xue L.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Jun;35(6):612-5. doi: 10.3969/j.issn.1672-7347.2010.06.012.

Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease?

Fitzgerald PJ.

Curr Alzheimer Res. 2010 Sep;7(6):506-16. doi: 10.2174/156720510792231775.

[Animal models of Alzheimer's disease for preclinical research.]

Takahashi H.

Nihon Yakurigaku Zasshi. 2010 Jul;136(1):6-10. doi: 10.1254/fpj.136.6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias